Sarah Boyce is CEO & President at Avidity Biosciences, Inc. (RNA). They have made 8 open-market trades across 5 companies since 2016, most recently 2026-09-18.
CIK 0001629383
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $159K since 2022, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RNA | SELL · 10b5-1 | 2026-01-21 | 2026-01-23 | $72.45 | $1.0M | +0.2% | +0.5% | -80.9% |
| RNA | SELL · 10b5-1 | 2026-01-07 | 2026-01-09 | $72.23 | $619K | +0.6% | +0.8% | -81.0% |
| RNA | SELL · 10b5-1 | 2025-09-05 | 2025-09-05 | $49.95 | $2.5M | -18.1% | -5.6% | +46.2% |
| RNA | SELL · 10b5-1 | 2025-08-28 | 2025-08-29 | $49.39 | $1.2M | -13.5% | -10.1% | +51.2% |
| RNA | SELL · 10b5-1 | 2025-03-20 | 2025-03-21 | $31.06 | $2.0M | -4.0% | -8.0% | -5.5% |
| RNA | SELL · 10b5-1 | 2025-01-21 | 2025-01-23 | $28.59 | $595K | +12.2% | +2.7% | +3.2% |
| RNA | SELL · 10b5-1 | 2024-12-18 | 2024-12-19 | $32.66 | $2.1M | +0.8% | -0.3% | +2.6% |
| RNA | SELL · 10b5-1 | 2024-09-23 | 2024-09-23 | $44.00 | $1.4M | +6.2% | +2.5% | -28.6% |
| RNA | SELL · 10b5-1 | 2024-08-06 | 2024-08-07 | $43.35 | $1.2M | +9.2% | -2.7% | +8.4% |
| RNA | SELL · 10b5-1 | 2024-07-09 | 2024-07-11 | $39.93 | $1.1M | +2.2% | -1.1% | +1.7% |
| RNA | SELL · 10b5-1 | 2024-06-18 | 2024-06-20 | $39.13 | $2.5M | +1.2% | +20.8% | +16.4% |
| RNA | SELL · 10b5-1 | 2024-06-12 | 2024-06-14 | $38.63 | $23.2M | +3.1% | +16.0% | +5.0% |
| RNA | SELL · 10b5-1 | 2024-06-04 | 2024-06-05 | $27.42 | $768K | +42.2% | +40.1% | +47.2% |
| RNA | SELL · 10b5-1 | 2024-05-07 | 2024-05-07 | $25.54 | $715K | +15.7% | +2.2% | +65.6% |
| RNA | SELL · 10b5-1 | 2024-04-02 | 2024-04-03 | $26.25 | $735K | -10.9% | -1.5% | +44.5% |
| RNA | SELL · 10b5-1 | 2024-03-08 | 2024-03-12 | $21.70 | $2.4M | +5.7% | +13.1% | +20.9% |
| RNA | SELL · 10b5-1 | 2024-03-01 | 2024-03-05 | $20.13 | $1.7M | +27.3% | +23.5% | +40.3% |
| RNA | SELL · 10b5-1 | 2024-01-22 | 2024-01-23 | $10.13 | $103K | +13.9% | +42.4% | +136.6% |
| RNA | SELL | 2023-02-01 | 2023-02-03 | $24.35 | $2.4M | +2.3% | -7.5% | -53.6% |
| OABI | BUY | 2022-11-09 | 2022-11-14 | $2.79 | $159K | -13.0% | +16.0% | +27.2% |
| RNA | SELL | 2022-08-24 | 2022-08-26 | $22.92 | $1.5M | +5.6% | -12.4% | -41.4% |
| RNA | SELL · 10b5-1 | 2022-08-15 | 2022-08-17 | $22.47 | $2K | +4.4% | +0.0% | -31.3% |
| BLI | SELL | 2021-03-01 | 2021-03-03 | $61.13 | $1.0M | -6.1% | -11.2% | -26.7% |
| AKCA | SELL | 2019-07-15 | 2019-07-17 | $23.52 | $43K | -2.2% | -4.4% | -9.6% |
| IONS | SELL | 2018-01-16 | 2018-01-17 | $51.76 | $227K | +2.8% | -2.8% | -13.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.